Mechanism of transcriptional activation of viral and cellular genes by oncogenic protein of HTLV-1 (Meeting abstract). NLM AIDSLINE Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Mechanism of transcriptional activation of viral and cellular genes by oncogenic protein of HTLV-1 (Meeting abstract).

International Association for Comparative Research on Leukemia and Related Diseases, 16th Symposium. July 11-16, 1993, Montreal, Quebec, Canada, A38, 1993.. Unique Identifier : AIDSLINE ICDB/94698640
Yoshida M; Dept. of Cellular and Molecular Biology, Inst. of Medical; Science, Univ. of Tokyo, Tokyo 108, Japan


Abstract: A human retrovirus, HTLV-1, is known as an etiologic agent for adult T-cell leukemia (ATL) and tropical spastic paraparesis (HAM/TSP). The regulatory gene tax appeared to enhance expression of the viral genes and also of certain cellular genes. Through the activation of some cellular genes, Tax has been proposed to contribute to abnormal proliferation of infected T cells and to production of various cytokines that are frequently associated with phenotypes of the diseases. The responsive elements for Tax transactivation have been identified as a 21-bp enhancer in the LTR, the NF-kappa B binding site of the IL-2R alpha and the CArG box of c-fos genes. It does not bind to these enhancer DNAs by its alone, thus participation of some cellular proteins has been proposed. Our previous observation using GAL-4 Tax fusion protein suggested that direct binding of the fusion protein to the DNA through GAL4 domain is required for the activation, thus, indirect association of Tax protein to the specific enhancers has been proposed. Such interaction might be mediated through enhancer binding proteins that bind to Tax protein. To identify cellular proteins contribute to the transactivation, we studied proteins that bind to the enhancer and to Tax protein. We found that leucine zipper proteins, CREB (CRE binding protein) and CREM (CRE modulator protein), do bind to Tax protein and then bind to the CRE sequence of DNA. The Tax also found to bind to a precursor p105 of the NF-kappa B. These bindings were characterized and their involvements in the transactivation mediated by Tax.
Keywords: DNA/GENETICS DNA-Binding Protein, Cyclic AMP-Responsive/GENETICS DNA-Binding Proteins/GENETICS Fungal Proteins/GENETICS Gene Products, tax/*GENETICS Genes, fos Human HIV Enhancer/GENETICS HIV Long Terminal Repeat/GENETICS Interleukin-2/METABOLISM Leucine Zippers/GENETICS NF-kappa B/GENETICS *Trans-Activation (Genetics) ABSTRACTKWDdna/geneticsdna-bindingprotein,cyclicamp-responsive/geneticsdna-bindingproteins/geneticsfungalproteins/geneticsgeneproducts,tax/KWDgeneticsgenes,foshumanhivenhancer/geneticshivlongterminalrepeat/geneticsinterleukin-2/metabolismleucinezippers/geneticsnf-kappab/geneticsKWDtrans-activation(genetics)abstract
940830
M9480801

Copyright © 1994 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .